Search Results - Laille, Eric J.

  • Showing 1 - 13 results of 13
Refine Results
  1. 1
    Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)

    Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015) by Rubio-San-Simón, Alba, van Eijkelenburg, Natasha K. A., Hoogendijk, Raoull, Hasle, Henrik, Niemeyer, Charlotte M., Dworzak, Michael N., Zecca, Marco, Lopez-Yurda, Marta, Janssen, Julie M., Huitema, Alwin D. R., van den Heuvel-Eibrink, Marry M., Laille, Eric J., van Tinteren, Harm, Zwaan, Christian M.

    Published in Paediatric drugs
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Azacitidine

    Azacitidine by Rubio-San-Simón, Alba, van Eijkelenburg, Natasha K. A, Hoogendijk, Raoull, Hasle, Henrik, Niemeyer, Charlotte M, Dworzak, Michael N, Zecca, Marco, Lopez-Yurda, Marta, Janssen, Julie M, Huitema, Alwin D.R, van den Heuvel-Eibrink, Marry M, Laille, Eric J, van Tinteren, Harm, Zwaan, Christian M

    Published in Paediatric drugs
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies

    Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies by Laille, Eric, Shi, Tao, Garcia-Manero, Guillermo, Cogle, Christopher R, Gore, Steven D, Hetzer, Joel, Kumar, Keshava, Skikne, Barry, MacBeth, Kyle J

    Published in PloS one
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed o... by Jain, Nitin, Chevallier, Patrice, Liu, Hongtao, Schiller, Gary J., Méar, Jean-Baptiste, DeAngelo, Daniel J., Curran, Kevin J, Grupp, Stephan, Baruchel, Andre, Balsat, Marie, LaCroce, Alexandra, Roudet, Caroline, Korngold, Ana B., Newhall, Kathryn J., Laille, Eric, Lee, Daniel J., Frattini, Mark G., Larson, Richard A., Boissel, Nicolas

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    P1408: UPDATED RESULTS OF THE PHASE I BALLI‐01 TRIAL OF UCART22, AN ANTI‐CD22 ALLOGENEIC CAR‐T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B‐ALL)

    P1408: UPDATED RESULTS OF THE PHASE I BALLI‐01 TRIAL OF UCART22, AN ANTI‐CD22 ALLOGENEIC CAR‐T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B‐CELL ACUTE LYMPHO... by Boissel, Nicolas, Chevallier, Patrice, Curran, Kevin, Schiller, Gary, Liu, Hongtau, Larson, Richard, Deangelo, Daniel J., Mear, Jean‐Baptiste, Grupp, Stephan, Baruchel, André, Konopleva, Marina, Lacroce, Alexandra, Roudet, Caroline, Korngold, Ana, Newhall, Katie, Laille, Eric, Lee, Daniel, Frattini, Mark, Jain, Nitin

    Published in HemaSphere
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

    Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors by Von Hoff, Daniel D, Rasco, Drew W, Heath, Elisabeth I, Munster, Pamela N, Schellens, Jan H M, Isambert, Nicolas, Le Tourneau, Christophe, O'Neil, Bert, Mathijssen, Ron H J, Lopez-Martin, Jose A, Edenfield, W Jeff, Martin, Miguel, LoRusso, Patricia M, Bray, Gordon L, DiMartino, Jorge, Nguyen, Aaron, Liu, Kejian, Laille, Eric, Bendell, Johanna C

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  7. 7
    Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry

    Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry by Derissen, Ellen J.B., Hillebrand, Michel J.X., Rosing, Hilde, Otten, Hans M.M.B., Laille, Eric, Schellens, Jan H.M., Beijnen, Jos H.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule

    Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule by Laille, Eric, Shi, Tao, Garcia-Manero, Guillermo, Cogle, Christopher R., Gore, Steven D., Kumar, Keshava J., Skikne, Barry S., MacBeth, Kyle J.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  9. 9
    Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML)

    Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML) by Gore, Steven D., Cogle, Christopher R., Skikne, Barry, Laille, Eric, Shi, Tao, MacBeth, Kyle J., Giordano, Heidi, Garcia-Manero, Guillermo

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  10. 10
    Abstract B217: A Phase I study of CC-486 (oral azacitidine) to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of azacitidine administered alone and in combination with carboplatin or ABI-007 (NAB-paclitaxel) in subjects with solid tumors

    Abstract B217: A Phase I study of CC-486 (oral azacitidine) to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of azacitidine administered alone and in combination wit... by Laille, Eric, Nguyen, Aaron N., Chen, Gengxi, Rasco, Drew, LoRusso, Patricia, Von Hoff, Daniel D., Bendell, Johanna, Munster, Pamela, Edenfield, William J., Ramanathan, Ramesh, Gonzalez, Michael B., Blackwood-Chirchir, Anne, DiMartino, Jorge

    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study

    Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study by Garcia-Manero, Guillermo, Gore, Steven D., Cogle, Christopher R., Jabbour, Elias J., Ward, M. Renee, MacBeth, Kyle J., Laille, Eric, Giordano, Heidi, Kantarjian, Hagop M., Skikne, Barry S.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  12. 12
    A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

    A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or... by Garcia-Manero, Guillermo, Gore, Steven D., Skikne, Barry, Cogle, Christopher R., Ning, Yuhong, MacBeth, Kyle J, Laille, Eric, Ward, M. Renee

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  13. 13
    A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study

    A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS)... by MacBeth, Kyle J, Laille, Eric, Ning, Yuhong, Cogle, Christopher R., Skikne, Barry, Gore, Steven D., Garcia-Manero, Guillermo, Ward, M. Renee

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: